|
BCX4430 (Immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog).〔Kamat SS, Burgos ES, Raushel FM. Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate. ''Biochemistry''. 2013 Oct 22;52(42):7366-8. DOI 10.1021/bi4013287 PMID 24111876〕 It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection,〔 and development for use in humans is being fast-tracked due to concerns about the lack of treatment options for the ongoing Ebola virus epidemic in West Africa.〔(BioWar Lab Helping To Develop Treatment For Ebola. Paul Rodgers, Forbes Magazine. 8 April 2014 )〕 ==See also== * Brincidofovir * DZNep * Favipiravir * FGI-106 * JK-05 * Lamivudine * Ribavirin * TKM-Ebola * Triazavirin * ZMapp 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「BCX4430」の詳細全文を読む スポンサード リンク
|